The mechanistic of DCBLD2 in inhibiting TGF-β induced endothelial-mesenchymal transition in calcific aortic valve disease

Weiwei Yang

doi:10.1016/j.yjmcc.2026.05.009

The mechanistic of DCBLD2 in inhibiting TGF-β induced endothelial-mesenchymal transition in calcific aortic valve disease

2026-05-24

0

PRE

AI

W

Weiwei Yang

Q

Qi Feng

C

Chao Yu

L

Lijing Li

S

Siran Zhang

Q

Qihao Nie

R

Runtao Wang

Y

Yanhong Zong

L

Lingling Guo

X

Xiaoning Liu

C

Chenyang Li

W

Wenjun Zhang

Y

Yunli Pei

H

Huifang Wang

D

Demin Liu *

H

Honglin Niu *

L

Lei Nie *

DOI：10.1016/j.yjmcc.2026.05.009

Original

Original request for help

Save

Abstract

En 中文

• First demonstration of DCBLD2's key protective role in CAVD. • DCBLD2 inhibits TGF-β/Smad signaling to block EndMT. • Targeted DCBLD2 enhancement alleviates valve calcification in vitro and in vivo. • Proposes DCBLD2 as a novel therapeutic target for CAVD.

Keywords:

DCBLD2

TGF-β/Smad signaling

EndMT

calcific aortic valve disease

therapeutic target

The mechanistic of DCBLD2 in inhibiting TGF-β induced endothelial-mesenchymal transition in calcific aortic valve disease

Abstract

Journal

Organization

Cited Papers

Citing Papers